File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection

TitleRabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection
Authors
Issue Date2001
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
Citation
Alimentary Pharmacology And Therapeutics, 2001, v. 15 n. 12, p. 1959-1965 How to Cite?
AbstractBackground: Rabeprazole is a new proton pump inhibitor with more potent acid suppressive and anti-Helicobacter effects. Aim: To compare two different regimens of rabeprazole-based triple therapy vs. 7-day omeprazole-based triple therapy for the eradication of Helicobacter pylori infection. Method: Patients with proven H. pylori infection were randomized to receive: (i) 7-day rabeprazole, 10 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg, all twice daily; (ii) 3-day rabeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg, all twice daily; or (iii) 7-day omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg, all twice daily. Endoscopy (CLO test, histology) was performed before randomization and 6 weeks after drug treatment. Results: One hundred and seventy-three patients were randomized. H. pylori eradication rates (intention-to-treat, n = 173/per protocol, n = 167) were 88%/91% for 7-day rabeprazole-based therapy, 72%/72% for 3-day rabeprazole-based therapy and 82%/89% for 7-day omeprazole-based therapy, respectively. The per protocol eradication rate was significantly better in the 7-day rabeprazole-based therapy and 7-day omeprazole-based therapy groups when compared to the 3-day rabeprazole-based therapy group (P = 0.01 and P = 0.04 respectively). Compliance was excellent and all three regimens were well tolerated. Conclusions: The efficacy of seven-day rabeprazole-based triple therapy is similar to 7-day omeprazole-based triple therapy for the eradication of H. pylori infection.
Persistent Identifierhttp://hdl.handle.net/10722/162544
ISSN
2015 Impact Factor: 6.32
2015 SCImago Journal Rankings: 2.833
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, BCYen_US
dc.contributor.authorWong, WMen_US
dc.contributor.authorYee, YKen_US
dc.contributor.authorHung, WKen_US
dc.contributor.authorYip, AWCen_US
dc.contributor.authorSzeto, MLen_US
dc.contributor.authorLi, KFen_US
dc.contributor.authorLau, Pen_US
dc.contributor.authorFung, FMYen_US
dc.contributor.authorTong, TSMen_US
dc.contributor.authorLai, KCen_US
dc.contributor.authorHu, WHCen_US
dc.contributor.authorYuen, MFen_US
dc.contributor.authorHui, CKen_US
dc.contributor.authorLam, SKen_US
dc.date.accessioned2012-09-05T05:20:57Z-
dc.date.available2012-09-05T05:20:57Z-
dc.date.issued2001en_US
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2001, v. 15 n. 12, p. 1959-1965en_US
dc.identifier.issn0269-2813en_US
dc.identifier.urihttp://hdl.handle.net/10722/162544-
dc.description.abstractBackground: Rabeprazole is a new proton pump inhibitor with more potent acid suppressive and anti-Helicobacter effects. Aim: To compare two different regimens of rabeprazole-based triple therapy vs. 7-day omeprazole-based triple therapy for the eradication of Helicobacter pylori infection. Method: Patients with proven H. pylori infection were randomized to receive: (i) 7-day rabeprazole, 10 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg, all twice daily; (ii) 3-day rabeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg, all twice daily; or (iii) 7-day omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg, all twice daily. Endoscopy (CLO test, histology) was performed before randomization and 6 weeks after drug treatment. Results: One hundred and seventy-three patients were randomized. H. pylori eradication rates (intention-to-treat, n = 173/per protocol, n = 167) were 88%/91% for 7-day rabeprazole-based therapy, 72%/72% for 3-day rabeprazole-based therapy and 82%/89% for 7-day omeprazole-based therapy, respectively. The per protocol eradication rate was significantly better in the 7-day rabeprazole-based therapy and 7-day omeprazole-based therapy groups when compared to the 3-day rabeprazole-based therapy group (P = 0.01 and P = 0.04 respectively). Compliance was excellent and all three regimens were well tolerated. Conclusions: The efficacy of seven-day rabeprazole-based triple therapy is similar to 7-day omeprazole-based triple therapy for the eradication of H. pylori infection.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APTen_US
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_US
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.-
dc.subject.mesh2-Pyridinylmethylsulfinylbenzimidazolesen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAnti-Ulcer Agents - Adverse Effects - Therapeutic Useen_US
dc.subject.meshBenzimidazoles - Adverse Effects - Therapeutic Useen_US
dc.subject.meshDiarrhea - Chemically Induceden_US
dc.subject.meshDrug Resistanceen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshDuodenal Ulcer - Prevention & Controlen_US
dc.subject.meshExanthema - Chemically Induceden_US
dc.subject.meshFemaleen_US
dc.subject.meshHelicobacter Infections - Drug Therapy - Microbiologyen_US
dc.subject.meshHelicobacter Pylori - Drug Effects - Isolation & Purificationen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOmeprazole - Adverse Effects - Therapeutic Useen_US
dc.subject.meshProton-Translocating Atpases - Antagonists & Inhibitorsen_US
dc.subject.meshStomach Ulcer - Prevention & Controlen_US
dc.subject.meshTime Factorsen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleRabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infectionen_US
dc.typeArticleen_US
dc.identifier.emailWong, BCY:bcywong@hku.hken_US
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_US
dc.identifier.authorityWong, BCY=rp00429en_US
dc.identifier.authorityYuen, MF=rp00479en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1046/j.1365-2036.2001.01118.xen_US
dc.identifier.pmid11736727en_US
dc.identifier.scopuseid_2-s2.0-0035668317en_US
dc.identifier.hkuros72111-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035668317&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume15en_US
dc.identifier.issue12en_US
dc.identifier.spage1959en_US
dc.identifier.epage1965en_US
dc.identifier.isiWOS:000172788300015-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridWong, BCY=7402023340en_US
dc.identifier.scopusauthoridWong, WM=7403972413en_US
dc.identifier.scopusauthoridYee, YK=7004400469en_US
dc.identifier.scopusauthoridHung, WK=26027012100en_US
dc.identifier.scopusauthoridYip, AWC=7004871369en_US
dc.identifier.scopusauthoridSzeto, ML=6602526385en_US
dc.identifier.scopusauthoridLi, KF=9036854600en_US
dc.identifier.scopusauthoridLau, P=11639863300en_US
dc.identifier.scopusauthoridFung, FMY=7003833944en_US
dc.identifier.scopusauthoridTong, TSM=7102587364en_US
dc.identifier.scopusauthoridLai, KC=7402135595en_US
dc.identifier.scopusauthoridHu, WHC=25932937100en_US
dc.identifier.scopusauthoridYuen, MF=7102031955en_US
dc.identifier.scopusauthoridHui, CK=7202876933en_US
dc.identifier.scopusauthoridLam, SK=7402279473en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats